This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Substantial reduction in losses
The company is eligible for 12 months exclusivity from launch
Subscribe To Our Newsletter & Stay Updated
